EDGC, with EDGC HealthCare and Solgent, promoted their clinical services at MEDLAB 2020 in Dubai, Feb. 3-6. Courtesy of EDGC
​

By Ko Dong-hwan

Korean genetics sequencing and analyzing firm EDGC turned heads at a major medical services and devices exhibition in Dubai, hinting it may finally enter the $11.4 billion Middle East market.

At MEDLAB 2020 on Feb. 3-6, the Incheon-based firm introduced clinical services such as personal genome sequencing, the non-invasive prenatal test NICE, liquid biopsies, customized healthcare products and molecular prognosis.

​
Its booth, introducing itself as a "total healthcare provider," was jointly prepared by its subsidiaries EDGC HealthCare and Solgent.

​
Some 100,000 people from 600 companies in 50 countries participated in the exhibition.

​
The EDGC booth saw about 500 participants interested in the company. Those from Europe, the Middle East, Africa and the Commonwealth of Independent States, including Russia and Uzbekistan, particularly inquired about NICE and liquid biopsies.

"Last year at MEDLAB, EDGC participated alone and only introduced the genome sequencing service," EDGC Vice President Yoo Jae-hyung said. "But this year, with our subsidiaries, we could present ourselves as a total healthcare service and thus attracted much more attention."

In December, EDGC announced at the National Neonatology Forum in India that it would establish EDGC India with the country's Rainbow Children's Hospital and the Phoenix Group, one of the country's 10 most powerful business conglomerates. The bid, according to EDGC, will allow the firm to enter India's $11 billion market with NICE.

Korea's Ministry of Trade and Industry in November selected NICE as one of the winners of the "Korean World-class Product Award 2019."

It was the first time a non-invasive prenatal test category won.